Mirum Pharmaceuticals, Inc.
MIRM
$96.55
$3.914.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.81% | 47.17% | 64.09% | 61.20% | 42.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.81% | 47.17% | 64.09% | 61.20% | 42.93% |
| Cost of Revenue | 24.07% | 22.74% | 15.79% | 29.10% | -8.95% |
| Gross Profit | 57.46% | 54.48% | 81.04% | 72.34% | 72.08% |
| SG&A Expenses | 30.44% | 22.48% | 28.61% | 26.44% | 23.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.15% | 26.53% | 30.03% | 32.48% | 21.05% |
| Operating Income | 81.15% | 120.52% | 79.41% | 42.64% | 25.67% |
| Income Before Tax | 79.63% | 119.03% | 77.26% | 44.64% | 31.24% |
| Income Tax Expenses | 233.16% | -175.50% | -36.69% | 64.90% | -356.00% |
| Earnings from Continuing Operations | 75.91% | 120.41% | 76.21% | 41.94% | 33.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.91% | 120.41% | 76.21% | 41.94% | 33.28% |
| EBIT | 81.15% | 120.52% | 79.41% | 42.64% | 25.67% |
| EBITDA | 108.30% | 230.71% | 105.81% | 56.11% | 32.94% |
| EPS Basic | 77.21% | 119.27% | 77.40% | 44.27% | 42.60% |
| Normalized Basic EPS | 80.72% | 117.94% | 78.40% | 46.86% | -253.72% |
| EPS Diluted | 75.41% | 116.67% | 77.40% | 44.27% | 42.80% |
| Normalized Diluted EPS | 80.72% | 115.96% | 78.40% | 46.86% | -253.72% |
| Average Basic Shares Outstanding | 5.63% | 5.98% | 5.28% | 4.18% | 16.23% |
| Average Diluted Shares Outstanding | 5.63% | 19.28% | 5.28% | 4.18% | 16.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |